Xlife Sciences AG (FRA:XLS) Research & Development: €0.00 Mil (TTM As of Dec. 2025)


FRA:XLS Xlife Sciences AG FRA:XLS
56 GF Score
Price €21.60
GF Value €7.80
Valuation Significantly Overvalued
! 10 Warning Signs
View Full Analysis

What is Xlife Sciences AG Research & Development?

Xlife Sciences AG FRA:XLS -2.70% 56 Research & Development is €0.00 Mil as of Dec. 2025. GuruFocus rates FRA:XLS with a GF Score™ of 56/100 and a GF Value™ of €7.80 (Significantly Overvalued). The stock has 10 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Xlife Sciences AG's Research & Development for the six months ended in Dec. 2025 was €0.00 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was €0.00 Mil.

Xlife Sciences AG  (FRA:XLS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Xlife Sciences AG Research & Development Related Terms

Xlife Sciences AG Research & Development Historical Data

* Premium members only.

The historical data trend for Xlife Sciences AG's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xlife Sciences AG Research & Development Chart

Xlife Sciences AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 0.22 0.15 0.27 0.02 0.00

Xlife Sciences AG Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.37 0.00 0.00 0.00 0.00
FRA:XLS
56GF Score
Xlife Sciences AG FRA:XLS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xlife Sciences AG Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of €0.00 Mil mean?
Xlife Sciences AG (FRA:XLS) has a Research & Development of €0.00 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Xlife Sciences AG and its competitors.
Is Xlife Sciences AG's Research & Development too high?
Xlife Sciences AG's current Research & Development is €0.00 Mil. Overall, Xlife Sciences AG has a GF Score™ of 56/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Research & Development compare to VRTX and REGN?
Xlife Sciences AG's Research & Development of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Xlife Sciences AG and its competitors. Xlife Sciences AG's current Research & Development is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (FRA:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is €7.80, compared to a current price of €21.60 — trading 176.9% above its estimated fair value. The current Research & Development is €0.00 Mil. Xlife Sciences AG's overall GF Score™ is 56/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Xlife Sciences AG (FRA:XLS), the current Research & Development is €0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xlife Sciences AG (FRA:XLS) Overvalued in 2026?

Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued. The current stock price of €21.60 is trading 176.9% above its estimated GF Value™ of €7.80. GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.

Key valuation signals for FRA:XLS:

  • Research & Development: €0.00 Mil
  • GF Value™: €7.80 vs. price of €21.60 (176.9% above fair value)
  • GF Score™: 56/100 with 10 warning signs

No single metric tells the full story. See the FRA:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xlife Sciences AG Business Description

Other Exchanges XLSz:UKXLS:Switzerland
Address Talacker 35, Zurich, CHE, 8001
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
56GF Score

Get the complete analysis for FRA:XLS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.60
Price
€7.80
GF Value